Pegfilgrastim

Coherus BioSciences Announces New Employment Inducement Grants

Retrieved on: 
Friday, June 19, 2020
Recombinant proteins, Life sciences, Medicine, Articles, Biosimilar, Biotechnology, Drugs, Pegfilgrastim, Filgrastim, NASDAQ, Recombinant proteins, Life sciences, Medicine, Articles, Biosimilar, Biotechnology, Drugs, Pegfilgrastim, Filgrastim, NASDAQ

The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Companys board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.

Key Points: 
  • The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Companys board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the United States and has received regulatory approval for UDENYCA in the European Union.

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention

Retrieved on: 
Monday, June 15, 2020
Medical specialties, Branches of biology, Anatomy, Recombinant proteins, Blood, Leukocytes, Neutropenia, Pegfilgrastim

The interim results have shown significant enhancement of the combination over Neulasta in the rate of Grade 4 neutropenia prevention (p

Key Points: 
  • The interim results have shown significant enhancement of the combination over Neulasta in the rate of Grade 4 neutropenia prevention (p
  • The PROTECTIVE-2 Phase 3 study is a double-blind, active controlled, global trial, with the pre-specified interim analysis at approximately 120 patients accrued.
  • The interim results also met its key secondary endpoint, the duration of severe neutropenia (DSN) in Cycle 1 (p
  • We are extremely excited about the topline results from the interim analysis of PROTECTIVE-2 Phase 3.

Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo® and Riximyo®

Retrieved on: 
Tuesday, June 9, 2020
Life sciences, Drugs, Biotechnology, Recombinant proteins, RTT, Biosimilar, Amgen, Novartis, Filgrastim, Pegfilgrastim, Rituximab

BOUCHERVILLE, Quebec, June 09, 2020 (GLOBE NEWSWIRE) -- Sandoz Canada Inc., a division of Novartis AG, announced today that Health Canada has approved Ziextenzo (pegfilgrastim, reference biologic drug: Neulasta) and Riximyo (rituximab, reference biologic drug: Rituxan) for marketing in Canada.

Key Points: 
  • BOUCHERVILLE, Quebec, June 09, 2020 (GLOBE NEWSWIRE) -- Sandoz Canada Inc., a division of Novartis AG, announced today that Health Canada has approved Ziextenzo (pegfilgrastim, reference biologic drug: Neulasta) and Riximyo (rituximab, reference biologic drug: Rituxan) for marketing in Canada.
  • Sandoz Canada received a Notice of Compliance from Health Canada on April 21, 2020, for the use of Ziextenzo to reduce the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy.
  • Sandoz Canada is a division of Sandoz International GmbH, a world leader in generics and biosimilars and a division of the Swiss multinational Novartis AG.
  • A true leader in its field, Sandoz Canada markets and distributes a wide range of generics, biosimilars and specialty products.

FDA Accepts for Review Fresenius Kabi’s BLA Submission for Pegfilgrastim Biosimilar

Retrieved on: 
Wednesday, May 27, 2020
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Medical specialties, Life sciences, Medicine, Recombinant proteins, Amgen, Biotechnology, Growth factors, Biosimilar, Drugs, Pegfilgrastim, Fresenius, Filgrastim

This is Fresenius Kabis first U.S. biosimilar regulatory submission.

Key Points: 
  • This is Fresenius Kabis first U.S. biosimilar regulatory submission.
  • Pegfilgrastim is used to reduce the incidence of infection associated with febrile neutropenia, a serious side effect of chemotherapy.
  • The acceptance of Fresenius Kabis submission of pegfilgrastim marks a key milestone as we seek approval for our first biosimilar in the United States, said John Ducker, president and CEO of Fresenius Kabi USA.
  • Fresenius Kabis BLA submission for its pegfilgrastim biosimilar candidate includes analytical, pharmacokinetic, pharmacodynamic, safety and immunogenicity data.

Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference

Retrieved on: 
Monday, May 4, 2020
Life sciences, Articles, Biotechnology, Recombinant proteins, Specialty drugs, Biosimilar, Drugs, Biopharmaceutical, Pegfilgrastim, Filgrastim

REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m.

Key Points: 
  • REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.

Coherus BioSciences to Report First Quarter Financial Results on May 7th

Retrieved on: 
Wednesday, April 22, 2020
Video game companies, Electronic Arts, Entertainment Software Association, NASDAQ, Pegfilgrastim, Video game industry, Companies

REDWOOD CITY, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020.

Key Points: 
  • REDWOOD CITY, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020.
  • ET, Coherus management team will host a conference call to discuss financial results and provide a general business update.
  • After releasing first quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com .
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.

Coherus BioSciences Announces New Employment Inducement Grants

Retrieved on: 
Friday, March 20, 2020
Recombinant proteins, Life sciences, Medicine, Articles, Biosimilar, Biotechnology, Drugs, Pegfilgrastim, Filgrastim, NASDAQ

The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Companys board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.

Key Points: 
  • The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Companys board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.

Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020

Retrieved on: 
Thursday, March 5, 2020
Recombinant proteins, Life sciences, Articles, Medicine, Biotechnology, Biosimilar, Drugs, Pegfilgrastim, Filgrastim, NASDAQ

REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m.

Key Points: 
  • REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.

United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand

Retrieved on: 
Thursday, March 5, 2020
Life sciences, Biotechnology, Biosimilar, Drugs, Pegfilgrastim, Natural sciences, Nature

REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today announced its United States manufacturing and distribution is well positioned to ensure uninterrupted availability of UDENYCA for patients.

Key Points: 
  • REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today announced its United States manufacturing and distribution is well positioned to ensure uninterrupted availability of UDENYCA for patients.
  • Reliable, high-quality supply is a key enabler to our mission of increasing patient access and delivering savings to the healthcare system.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.

Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference

Retrieved on: 
Wednesday, February 26, 2020
Recombinant proteins, Life sciences, Medicine, Branches of biology, Pegfilgrastim, Biosimilar, Filgrastim

REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m.
  • ET, being held in Boston.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.